— Know what they know.
Not Investment Advice
Also trades as: 0T6G.L (LSE) · $vol 0M

QTTB NASDAQ

Q32 Bio Inc.
1W: +1.0% 1M: -5.6% 3M: -40.5% YTD: +153.2% 1Y: +193.3% 3Y: -53.0% 5Y: -92.1%
$8.71
+0.26 (+3.08%)
 
Weekly Expected Move ±11.2%
$7 $8 $9 $10 $11
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 45 · $259.3M mcap · 13M float · 8.77% daily turnover · Short 51% of daily vol
Credit Risk of going bust: higher than 79% of companies Debt: 2.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 99.5%), Q32 Bio Inc. would be worth roughly what it owes.
Total debt $5.3M against a stock market value of $259.3M.
Distance to default 2.72 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.3M (short-term plus half of long-term), stock volatility 141.2%; Altman Z'' 12.11. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

📊 Key Metrics

TTM
$54M
Revenue
+0.0% YoY
$34M
Net Income
+164.6% YoY
$-20M
Free Cash Flow
+63.4% YoY
0.0%
Gross Margin
0.0%
Op. Margin
0.0%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE72.1%
ROA37.1%
ROIC435.2%

Valuation

P/E3.1
P/B1.2
EV/EBITDA3.5

Leverage

Debt/Equity0.05
Current Ratio20.30
Interest Cov.17.0x

Quality Scores

Piotroski F5/9
Altman Z10.31
Beneish M0.00

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms